Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma

Show simple item record

dc.contributor.author Fullen, Douglas R. en_US
dc.contributor.author Lowe, Lori en_US
dc.contributor.author Su, Lyndon D. en_US
dc.date.accessioned 2010-06-01T21:30:33Z
dc.date.available 2010-06-01T21:30:33Z
dc.date.issued 2003-02 en_US
dc.identifier.citation Fullen, Douglas R.; Lowe, Lori; Su, Lyndon D. (2003). "Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma." Journal of Cutaneous Pathology 30(2): 118-122. <http://hdl.handle.net/2027.42/74565> en_US
dc.identifier.issn 0303-6987 en_US
dc.identifier.issn 1600-0560 en_US
dc.identifier.uri http://hdl.handle.net/2027.42/74565
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12641790&dopt=citation en_US
dc.description.abstract Neurothekeoma is a benign tumor of putative peripheral nerve sheath origin. It occurs in a myxoid (classic) variant, cellular variant, and intermediate (mixed) variant. Cellular neurothekeoma (CNT) usually involves the head and neck or extremities of young patients. Histologically, CNT can be confused with melanocytic and fibrohistiocytic lesions. An immunohistochemical antibody panel is often necessary to confirm the histological impression and exclude melanocytic and/or fibrohistiocytic lesions. Methods: Formalin-fixed, paraffin-embedded archival tissues were evaluated by immunohistochemistry using antibodies specific for S100A6 and PGP9.5 in 11 cases of neurothekeoma (seven cellular, four myxoid). A variety of other antibodies were evaluated by immunohistochemistry at the time of initial diagnosis. Results: All 11 neurothekeoma cases were positive for S100A6 protein (four cases, weak/1+ ; seven cases, strong/2+), corresponding to 100% sensitivity. In contrast, eight of 11 neurothekeoma cases (73% sensitivity) were positive for PGP9.5. All seven CNT cases were negative for S100B, as expected. Conclusions: Anti-S100A6 is a highly sensitive antibody for neurothekeomas, including CNT, and, in our experience, is superior in sensitivity to PGP9.5. However, like other antibodies used in evaluating neurothekeomas, S100A6 lacks specificity, as has been demonstrated in previous studies. Nevertheless, S100A6 can be useful in an immunohistochemical antibody panel to evaluate lesions where the differential diagnosis includes CNT. Fullen DR, Lowe L, Su LD. Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma. en_US
dc.format.extent 6646805 bytes
dc.format.extent 3109 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.publisher Munksgaard International Publishers en_US
dc.publisher Blackwell Publishing Ltd en_US
dc.rights © Munksgaard 2002 en_US
dc.title Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma en_US
dc.subject.hlbsecondlevel Dermatology en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum Departments of Pathology and Dermatology, University of Michigan Hospitals, Ann Arbor, Michigan, MI, USA en_US
dc.identifier.pmid 12641790 en_US
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/74565/1/j.1600-0560.2002.00032.x.pdf
dc.identifier.doi 10.1034/j.1600-0560.2002.00032.x en_US
dc.identifier.source Journal of Cutaneous Pathology en_US
dc.identifier.citedreference Gallager RL, Helwig EB. Neurothekeoma – A benign cutaneous tumor of neural origin. Am J Clin Path 1980; 74: 759. en_US
dc.identifier.citedreference Harkin JC, Reed RJ. Tumors of the peripheral nervous system. In: Rosai J, Sobin LH (eds). Fascicle 3, 2nd edn. Washington DC: Armed Forces Institute of Pathology, 1969; 60. en_US
dc.identifier.citedreference Rosati LA, Fratamico FCM, Eusebi V. Cellular neurothekeoma. Appl Pathol 1986; 4: 186. en_US
dc.identifier.citedreference Argenyi ZB, LeBoit PE, Santa Cruz D, Swanson PE, Kutzner H. Nerve sheath myxoma (neurothekeoma) of the skin: light microscopic and immunohistochemical reappraisal of the cellular variant. J Cutan Pathol 1993; 20: 294. en_US
dc.identifier.citedreference Barnhill RL, Mihm MC. Cellular neurothekeoma: a distinctive variant of neurothekeoma mimicking nevomelanocytic tumors. Am J Surg Pathol 1990; 14: 113. en_US
dc.identifier.citedreference Calonje E, Wilson-Jones E, Smith NP, Fletcher CDM. Cellular ‘neurothekeoma’: an epithelioid variant of pilar leiomyoma? Morphological and immunohistochemical analysis of a series. Histopathology 1992; 20: 397. en_US
dc.identifier.citedreference Husain S, Silvers DN, Halperin AJ, McNutt NS. Histologic spectrum of neurothekeoma and the value of immunoperoxidase staining for S100 protein in distinguishing it from melanoma. Am J Dermatopathol 1994; 16: 496. en_US
dc.identifier.citedreference Zelger BG, Steiner H, Kutzner H, Maier H, Zelger B. Cellular ‘neurothekeoma’: An epithelioid variant of dermatofibroma? Histopathology 1998; 32: 414. en_US
dc.identifier.citedreference Busam KJ, Mentzel T, Colpaert C, Barnhill RL, Fletcher CDM. Atypical or worrisome features in cellular neurothekeoma. A study of 10 cases. Am J Surg Pathol 1998; 22: 1067. en_US
dc.identifier.citedreference Argenyi ZB, Kutzner H, Seaba MM. Ultrastructural spectrum of cutaneous nerve sheath myxoma/cellular neurothekeoma. J Cutan Pathol 1995; 22: 137. en_US
dc.identifier.citedreference Barnhill RL, Dickersin GR, Nickeleit V et al. Studies on the cellular origin of neurothekeoma: Clinical, light microscopic, immunohistochemical, and ultrastructural observations. J Am Acad Dermatol 1991; 25: 80. en_US
dc.identifier.citedreference Tomasini C, Aloi F, Pippione M. Cellular neurothekeoma. Dermatology 1996; 192: 160. en_US
dc.identifier.citedreference Wang AR, May D, Bourne P, Scott G. PGP. 9.5: a marker for cellular neurothekeoma. Am J Surg Pathol 1999; 23: 1401. en_US
dc.identifier.citedreference BÖni R, Burg G, Doguoglu A et al. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions. Br J Dermatol 1997; 137: 39. en_US
dc.identifier.citedreference Kuźnicki J, Filipek A, Heimann P, Kaczmarek L, Kamińska B. Tissue-specific distribution of calcyclin 10.5 kDa Ca2+-binding protein. FEBS Lett 1989; 254: 141. en_US
dc.identifier.citedreference Tonini GP, Casalaro A, Cara A, DiMartino D. Inducible expression of calcyclin, a gene with strong homology to S-100 protein, during neuroblastoma cell differentiation and its prevalent expression in Schwann-like cells. Cancer Res 1991; 51: 1733. en_US
dc.identifier.citedreference Fullen DR, Reed JA, Finnerty B, McNutt NS. S100A6 preferentially labels type C nevus cells and nevic corpuscles: Additional support for Schwannian differentiation of intradermal nevi. J  Cutan Pathol 2001; 28: 393. en_US
dc.identifier.citedreference Mackie RM, Campbell I, Turbitt ML. Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions. J Clin Pathol 1984; 37: 367. en_US
dc.identifier.citedreference Vennegoor C, Calafat J, Hageman P et al. Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NK1-C3. Int J Cancer 1985; 35: 287. en_US
dc.identifier.citedreference Gatter KC, Ralfkiaer E, Skinner J et al. An immunocytochemical study of malignant melanoma and its differential diagnosis from other malignant tumours. J Clin Pathol 1985; 38: 1353. en_US
dc.identifier.citedreference Mahalingam M, LoPiccolo D, Byers HR. Expression of PGP9. 5 in granular cell nerve sheath tumors: an immunohistochemical study of six cases. J Cutan Pathol 2001; 28: 282. en_US
dc.identifier.citedreference Zelger BW, Zelger BG, Steiner H, Ofner D. Aneurysmal and hemangiopericytoma-like fibrous histiocytoma. J Clin Pathol 1996; 49: 313. en_US
dc.identifier.citedreference Zelger BG, Sidoroff A, Zelger B. Combined dermatofibroma: coexistence of two or more variant patterns in a single lesion. Histopathology 2000; 36: 529. en_US
dc.identifier.citedreference Rode J, Dhillon AP, Doran JF, Jackson P, Thompson RJ. PGP. 9.5–a new marker for human neuroendocrine tumors. Histopathology 1985; 9: 147. en_US
dc.identifier.citedreference Thompson RJ, Doran JF, Jackson P, Dhillon AP, Rode J. PGP. 9.5–a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 1983; 278: 224. en_US
dc.identifier.citedreference Fullen DR, Reed JA, Finnerty B, McNutt NS. S100A6 expression in fibrohistiocytic lesions. J Cutan Pathol 2001; 28: 229. en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)


Search Deep Blue

Advanced Search

Browse by

My Account

Information

Coming Soon


MLibrary logo